1. Success Story of EstroG-100
Novel Proprietary Standardized Healthcare Ingredient
Naturalendo Tech Co., Ltd.

2. Company Profile - Facts & Figures
Established in May 24, 2001
Headquartered in Pangyo (10 minutes from Gangnam (Seoul)), Korea
Initial Public Offering: Oct 31st, 2013 in KOSDAQ
Business Lines:
Proprietary Herbal Remedy (EstroG-100)
IGF-1 Secretagogue (YGF-251)
Hormone Disruptor Inhibitor
Immune Enhancer
Skin Care Formula, etc.
2014 Sales Revenue: $ 124 mil. in 2014
In-house Manufacturing Facility
Fastest growing bio venture & largest biotech in terms of the sales of in-house developed health functional food ingredient in Korea

3. Summary of Healthcare Industry & Our Product Line-up
Characteristics of Healthcare Industry
Difficult to enter into a market due to long-term investment in R&D and a massive capital investment
High value-added industry
Service to the Public Health
Insensitive to Economy Fluctuation
Healthcare Industry
Device & Equipment
U – Healthcare
Pharmaceutical
Nutraceutical
Cosmeceutical
Others
Insurance
Health Machine
Hospital & Clinics
Novel Ingredient
Our Products
hGH Secretagogue
EstroG-100
Derma A2
TDDS

4. Function of Estrogen
Growth and development of uterus and mammary gland
Expression of secondary sex characteristics
Control of menstrual cycles and supporting pregnancy
Bone metabolism and increase of BMD
Cardiovascular health and lipid metabolism
Anti-dementia, trophic factor for neuron
Colon cancer prevention
Teeth health
Prevention of macular degeneration
Fat distribution to subcutaneous fat tissue
Collagen production and maintaining human skin

5. Menopause Classification
Premature Menopause
About 8% Women (US) stop having period before age 40
Same symptoms as Menopause
Peri-menopause
Average women go through this phase age 45~49
Wildly fluctuating Estrogen Level
Menopause
Estradiol level<50 pg/mL; FSH>50 mIU/mL; no period for >1 yr*
Average age for onset of menopause is 52 in US
Symptoms last 2~19 years, many more than 5 years
Surgical Menopause
After Hysterectomy/Bilateral surgery
* Definition: Dr. Joel Harglove, MD, Chairman, Vanderbilt Menopause Center, Nashville, TN

6. After Menopause, Women Suffer…
Women spend almost half of their lives in pre-, peri- and post-menopause.
Physiological /Psychological Changes During Menopause
Hot flashes, Night sweats
Vaginal dryness & thinning of vaginal wall
Inelastic skin and dry eye, insomnia, nervousness, depression, paresthesia(numbness), vertigo(dizziness), fatigue, rheumatic pain(joint), pounding of heart, headaches
Long Term Post-Menopausal Health Risks
Cardiovascular Diseases (CVD’s) : 2 times higher risk of CVD’s after menopause
Osteoporosis

7. EstroG-100

8. Executive Summary Solution for Women’s Quality of Life
EstroG-100 is dominating the Korean market by occupying over 90% share of total menopause market, including HRT and herbal remedies.
Features
Market Status
Benefits
Patents, Licenses, and approvals
17 registered and pending patents worldwide
Health Canada NPN License
NDI Notification Accepted by US FDA
HFFI by MFDS (Korea FDA)
Expected to obtain Novel Food Approval from EU Commission 1Q 2015
Successful sales in Korea, US, Canada and Southeast Asian countries.
Ranked No.1 over more than 45 products of HRT & Black cohosh since in Korea
Supplying to Korean major companies & its sales hit 340milliion USD in retail price in 2014
Clinically proven efficacy and safety
Significant improvement of 10 menopausal symptoms out of 12 in total
QOL improvement
FBMD significantly improved
No side effects compared to other alternatives including HRT, Black Cohosh and Isoflavone.

9. R&D & Commercialization of Novel Healthcare Ingredients
Competency
Production & Purchasing
In-house Manufacturing Site
Contract Farming
R&D Center
Diverse Pipeline & Differentiated R&D Patents
Marketing & Sales
Differentiated Marketing & Major Company Loyalty
R&D & Commercialization of
Novel Healthcare Ingredients

10. EstroG-100 a. Positioning in the industry

11. New History on Healthcare Ingredients
Sales of Major Herbal Medicines
(million USD)
Stillen: the Korean Blockbuster Herbal Medicine of Dong-A Pharm sold in US$85 mil.
Joins: the Korean Major Herbal Medicine of SK Chemical in US$35 mil. (Ministry of Health & Welfare, 2012)
Factive: the 1st Korean Drug approved by U.S. FDA sold in US$17 mil in 2011 but decreased to US$9 mil. in 2012 (Asia Economics, 2013)
Sales of EstroG-100 in Retail Price
(million USD)
EstroG-100 has been supplied for Korean majors and its sales hit in Retail Price:
USD mil.
USD 55 mil.
USD 100 mil.
USD 270 mil.
USD 340 mil.

12. Dominance in Korean Menopause Market
Market Share in Korea Menopause Market
(W100mn)
Began sales from Aug. 2010
Established $340m market
2014
Established $270m market
2013
Established U$100m market Dominating over Other Ingredients
2012
No.1 Ingredient in Korea
2011
* Total sales have been converted to consumer prices since we have been supplying EstroG in the type of ingredient, semi-finished products, finished products, and our own brands.
Source : Korea Pharmaceutical Manufacturers Association, Korea Export Association

13. Global Estrogen Market Share
Line-up of Major Global Partners  Global Sales to Increase
Pioneering potential global market
Replacing Global Pharma +
Supplement Market
2014
Major partners
in each country
2013
2012
Global
Supplement
companies
Big Pharma
* Global sales of HRT products and Naturalendo’s sales converted to consumer price.

14. Penetrating Global Market

15. EstroG-100 B. Competitors in the market

16. Other Estrogen Alternative - (1) HRT
Women’s Health Initiative Study (WHI)
National Institute of Health (NIH) sponsored 8.5-year study with 16,000 subjects to estimate the benefits and risks of HRT
The Study was terminated early at 5 years with increased risks of breast cancer (26%), CVD (22%), stroke (41%), coronary heart disease (29%), blood clots (100%), Alzheimer's (100%)
US FDA required “Black Box Warning”
Prescribed ONLY for <4 weeks
JAMA July 2002

17. Side effects of hormones reported Low-dose hormones release
Other Estrogen Alternative - (1) HRT
Negative Results of WHI’s Clinical Studies on HRT
In U.S., HRT prescription significantly dropped since 2002
“Soaring Needs for Safe and Natural Alternative, EstroG-100”
JAMA 2004; 291; 1770
Side effects of hormones reported
Non-hormones release
Low-dose hormones release
Ref: GBI Research (2009)

18. Other Estrogen Alternative - (2) Pomegranate
Pomegranate, just a fruit
“Any estrogen is not included under error range in this prove. In addition, any estrogen is proven not to be detected in 7 different pomegranate fruits. Coumestrol the phytoestrogen is not detected in the supplements either not as known to public to be included in the seeds.”
ザクロを使った健康志向食品 - エストロゲンは本当に含まれているの？
(Supplement using pomegranate – Estrogen included?)
国民生活センター, ［2000年4月6日:公表］
●結果・現状
　今回調べた範囲ではエストロゲンは検出限界以下で検出されなかった。また、延べ7個のザクロ果実を調べた結果でもエストロゲンが含有されていることの確認はできなかった。またザクロの種子に含まれていた植物ホルモンのクメステロールも健康志向食品からは検出されなかった。
独立行政法人国民生活センターの概要
(情報公開法第２２条に規定する情報の提供）
国民生活の安定及び向上に寄与するため、総合的見地から、
国民生活に関する情報の提供及び調査研究を行うこと。

19. Other Estrogen Alternative - (3) Black Cohosh
Vulnerability of Black Cohosh
The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) advised that a warning label would be placed on the all black cohosh products due to 21 reported cases of liver problems associated with black cohosh use (MHRA, 2006)
01/15/2007
07/30/2007
At the end of one year, there was no significant difference seen between the number of daily hot flashes and/or night sweats in any of the herbal groups compared to the placebo group, with an average of 0.6 less vasomotor symptoms per day in the herbal groups. There was a significant difference-4.06 fewer symptoms per day-in the hormone therapy group compared to the placebo groups
The committee reviewed case reports suggesting a potential link between ingestion of the extracts and liver damage

20. Other Estrogen Alternative - (3) Black Cohosh
As of Oct 2012, due to 36 out of 53 case reports related to black cohosh involved liver problem, MHRA has warned manufacturers of black cohosh products that the herbal supplements must contain warnings about potential liver problems (MHRA 2012).

21. Other Estrogen Alternative - (4) Isoflavone
Genistein (a major isoflavone aglycone) may cause Cancers
(NIH & FDA – National Toxicology Program, Genistein Final , Jan, 2008)
Exposure to Genistein for 2 years caused mammary gland /pituitary gland adenoma in female rats.
Exposure to Genistein for shorter duration following birth was also possibly associated with increased rates of pituitary gland and mammary gland tumors.
Cancer Causing Risks
Isoflavone Could be Toxic because its high level of hormone-like action.
It could be Hormone Dependent Cancer Causing Material due to its high binding affinity to Estrogen Receptor α, and β
Relative Binding Affinity α β
Estradiol
100
Coumestrol1) 94
185
Genistein2) 4 87
1) Kuiper et al, Vol 139, No. 3, Endo ) Vol 138, No. 10, Endo 1998,

22. EstroG-100’s Superiority over Others
Pomegranate
Soy Isoflavone
Black Cohosh
HRT
Improved Symptoms 10 1
(Hot Flush) X
Partially Some
Improved
Improvement of vaginal dryness O
Bone metabolism index
Bone density
O (FBMD)
O (Spine)
Triglycerides
Side Effects
Cancer Related
(limitation on dosage)
Liver Damage
Fatal Side Effects
Increase of Body Weight & BMI -
E2, FSH Changes
Development
In the 2000s
In 1998
In the 1990s
In the 1940s
Related Patents
17 registered and pending patents

23. Estrog C. Science of Estrog-100

24. EstroG-100 (1) Science of New Herbal Ingredient Proven Safety
About 400 years of documented use in Korea as folk medicine
Registered as safe food ingredient in Korea Food Code
Cynanchum wilfordii & Phlomis umbrosa are reported to be liver-protective plants to WHO
No increase of uterus weight in ovariectomized rat tests
Inhibition of proliferation of human breast cancer cell (MCF-7)
No binding Affinity to both Estrogen Receptor α and β,
Safe: Acute & Multi-dose toxicity tests , Genetic toxicity tests
Proven Efficacy in vitro, in vivo, and in 3 human group (Asian and non-Asian) clinical studies
Herbal extracts screened out of 71 herbal extracts via non-reproductive tract target tissue response
(E-screen test)
3 herbal extracts were chosen:
Cynanchum wilfordii, Phlomis umbrosa, and Angelica gigas nakai

25. Improve Menopausal Symptoms
EstroG-100 (2)
Clinically proven efficacy : 62% significant improvement of QOL
10 out of 12 climacteric symptoms significantly improved compared to Placebo
Improve Menopausal Symptoms
Hot flash/ Night Sweats
Paresthesia
Insomnia
Nervousness
Melancholia
Vertigo
Fatigue
Rheumatic pain
Formication
Vaginal Dryness
62%
Improvement of symptoms

26. Clinical Study I Protocol Efficacy Clinical Study I
Test Method
Randomized Double-blind Placebo-controlled study
Study Location
School of Medicine, Sungkyunkwan Univ. Samsung Cheil Hospital
Dosing period
12 months (May 2003-April 2004)
Evaluation Style
Long Term Safety Evaluation
Patients (n=47)
23 subjects in placebo group & 24 active group
Inclusion Criteria
Age of 46 ~ 66 & Diagnosis of menopausal syndromes (average age=54)
Efficacy
Climacteric Symptoms 5 times better improvement than placebo with significance
Climacteric Symptoms 5 times better improvement than
placebo with significance
After 3 months
OR=5.04 (95% C.I.= )
Fisher’s Exact Test
Femoral Bone Mineral Density
0.746±0.10 → 0.763±0.13 (P<0.05)
Serum hGH Level
0.25±0.21 → 0.92±0.97 (ng/mL) (P<0.05)
Serum Osteocalcin Level
6.02±2.74 → 5.66±3.01 (ng/mL) (P<0.05)
Serum Triglyceride Level
119.1±54.72 → 92.16±49.94 (mg/dL) (P=0.066)
Serum Alkaline Phosphatase Level
73.35±21.02 → 60.42±14.87 (IU/L) (P=0.08)

27. Clinical Study II - Protocol(Non-Asian)
Randomized, Double-blind, Placebo-controlled Study (CA, USA)
Dosing period
3 months
Patients (n=61)
32 subjects in placebo group & 29 active group
Inclusion Criteria
Age of 42 ~ 70, Diagnosis of menopausal syndromes(average age = 53)
Ad for Volunteers for US Clinical Study

28. Clinical Study II – Result (1)
Efficacy of EstroG-100
Kupperman Menopause Index and Vaginal Dryness (Difficulties in Sexual Intercourse) Improved Significantly
Somatic / Physical:
Hot flush/ Night sweat
Paresthesia (numbness on hands/foot)
Vertigo (dizziness)
Fatigue
Muscular skeletal pain
Physiological / Psychological:
Nervousness
Insomnia
Depression
Formication
Vaginal Dryness (Difficulties in Sexual Intercourse)
EstroG-100 was confirmed to improve both somatic and physiological symptoms with statistic significance.

29. Clinical Study II – Result (2)
Vaginal Dryness
Vaginal Dryness Improved Unlike Black cohosh and Isoflavone
EstroG-100
Mean±SE
Placebo
Week0 (Baseline)
1.45±1.02
1.75±1.11
Week6
Change from baseline
0.72±0.88
-0.72±0.84**††##
1.50±1.11
-0.25±0.57#
Week12
0.59±0.87
-0.86±0.88*##
1.28±1.02
-0.47±0.72##
P=0.0536
Vaginal dryness scores
Fig. 1. Changes of vaginal dryness and reduced libido during 12 weeks administration of EstroG-100 and placebo.
SE: Standard Error
*: Statistically significant compared between groups; p<0.05 by t–test(ITT)
**: Statistically significant compared between groups; p<0.01 by t–test(ITT)
††; p<0.01 compared between groups by Wilcoxon rank sum test
#; p-<0.05 compared to baseline, ##; p<0.01 compared to baseline by paired t-test

30. Clinical Study II – Result (3)
KMI
Kupperman Index for Moderate or Severe Menopausal Symptoms Improved
EstroG-100
Mean±SE
Placebo
Week0 (Baseline)
29.45±7.39
29.16±6.55
Week6
Change from baseline
13.62±7.61
-15.83±9.10**††##
23.31±8.96
-5.84±6.15##
Week12
11.31±5.78
-18.14±8.46**††##
23.66±7.68
-5.50±5.34##
Kupperman index scores
Time (weeks)
Fig. 2. Changes of Kupperman Menopause Index(Mean±SE) during 12 weeks administration of EstroG-100 and placebo.
SE: Standard Error
**: Statistically significant compared between groups; p<0.01 by t–test(ITT)
††; p<0.01 compared between groups by Wilcoxon rank sum test
##; p<0.01 compared to baseline by paired t-test

31. Clinical Study II – Result (4)
Individual Menopausal Symptoms
EstroG-100 (n=29)
Placebo (n=32)
Week 0
Week 6
Week 12
Vasomotor
2.24±0.69
1.03±0.82**††##
0.79±0.73**††##
2.22±0.66
1.78±0.75##
2.06±0.76
Paresthesia
1.31±0.85
0.59±0.78*†##
0.55±0.74*†##
1.41±0.91
1.13±0.94#
1.09±0.96##
Insomnia
2.28±0.84
1.28±0.96**†##
0.97±0.82**††##
2.03±0.86
1.63±1.01#
1.63±0.87#
Nervousness
1.72±0.88
0.76±0.69**††##
0.66±0.67**††##
1.56±0.84
1.22±0.83
1.34±0.75
Melancholia
1.93±0.88
1.03±0.68**††##
0.83±0.71**††##
1.59±0.95
1.31±0.93
1.31±0.74
Dizziness
0.97±0.82
0.21±0.49**††##
0.21±0.41**††##
0.75±0.72
0.72±0.77
0.59±0.80
Fatigue
2.21±0.77
0.90±0.77**††##
0.72±0.70**††##
2.00±0.88
1.69±0.90#
1.59±0.80#
Arthritic Pain
1.59±1.02
0.79±0.94**†##
0.55±0.78*†##
1.84±0.95
1.63±0.83
1.47±0.88
Headache
1.34±1.04
0.69±0.76##
0.66±0.77##
1.53±0.95
1.13±0.91#
0.84±0.72##
Palpitation (heart poundering)
1.00±0.96
0.48±0.69#
0.55±0.63#
0.91±0.82##
0.75±0.84##
Formication
0.83±0.85
0.14±0.44* ##
0.28±0.45##
1.25±1.05
0.88±1.01##
0.72±0.96##
*; p-<0.05 compared between groups, **; p<0.01 compared between groups by t –test †; p-<0.05 compared between groups, ††; p<0.01 compared between groups by Wilcoxon rank sum test, #; p-<0.05 compared to baseline, ##; p<0.01 compared to baseline by paired t-test

32. Clinical Study III - Protocol
Test Method
Multi Center,
Randomized double-blind placebo-controlled study
Study Location
Aju University Medical Center
Anam Hospital of Korea University
Severance Hospital of Yonsei University
Test period
12 weeks
Dosage
638 mg tablet orally twice a day
Study Participants
96 female participants of age of 40~70 with menopausal symptoms
Inclusion Criteria
Age of 40 ~ 70 with menopausal symptoms

33. Clinical Study III - Result
Significantly Improved!
Hot flash
Paresthesia
Nervousness
Melancholia
Vertigo
Fatigue
Formication
Rheumatic pain
Vaginal Dryness
The result almost duplicate the 2nd Clinical Study (Non-Asian) by improving as many as 10 different symptoms.
No significant differences or changes observed when measured endometrial thickness.
No change in weight, BMI, and the level of estrogen and FSH without any adverse event reported during the study. The endometrial thickness was measured to be observed not to change in addition.

34. Efficacy of EstroG-100 (1) Estrogenicity
In e-screen test, the estrogen-specific alkaline phosphatase has significantly increased and synergetic effects of EstroG-100 has been confirmed
E-screen test: Screen herbal extracts for Estrogenicity
Synergetic Effects of 3 Constituent herbal extracts confirmed
Lee at al., Lab. Anim. Res. 24(2): (2008)
Uterus weight
Serum osteocalcin
FBMD
Significantly improved in serum osteocalcin and FBMD in OVX rat
No change in weight, liver, kidney, and uterus weight in OVX rat
Kim at al., Kor. J Food Sci. Technol. 40(3): (2008)

35. Efficacy of EstroG-100 (2)
75% higher satisfaction rate compared to the existing Isoflavone product
69% picked “Better Efficacy” for the top reason for the higher satisfaction
* One month Open Label Clinical Study by HiLiving, the No.1 MLM firm among local capital MLM companies in Korea with 119 participants

36. Efficacy of EstroG-100 (3)
86% decrease in menopausal symptoms compared to 39% of the Isoflavone product
Sales volume increased 2.5 times, satisfaction/repurchasing/ recommendation rate soared
* One Month Open Label Clinical Study by Pulmuone Health Care with 31 participants

37. Efficacy of EstroG-100 (4)
Wrinkles, Hot Flashes, and Moisture Significantly Improved
* One month Open Label Clinical Study by LG Household & Health Care for 6 weeks with 30 participants

38. Restarting menstruation
Efficacy of EstroG-100 (5)
Symptoms
Cases %
Hot flush 11
20%
Paresthesia 4 7%
Insomnia 3 6%
Nervousness
Melancholia
Vertigo
Fatigue 5 9%
Rheumatic pain
Formication 2 4%
Headache
Palpitation
Vaginal dryness 7
13%
PMS
Menstrual pain
Restarting menstruation 1 2%
Total 54
100%
Hot flush and vaginal dryness, 33 % of total improved cases.
Out of 20 participants, 10 participants showed the improvement of menopausal symptoms within 7 days after taking EstroG-100. The main improvement symptoms were hot flush and vaginal dryness, 33 % of total improved cases.
* Open Label Clinical Study by Kim Jung Moon Aloe for 4 weeks with 20 participants

39. Safety of EstroG-100 (1) Safety in 3 human clinical studies
No serious adverse effects – not even a single case of vaginal bleeding / spotting
No change in uterus weight, body weight and BMI (while bone mineral density increase)
None of serious side effects reported in 3 clinical studies without E2, FSH level change
No change in blood pressure, blood sugar, cholesterol, LDL/HDL
No change in endometrial thickness
Other Proven features
All three herbs have been documented for use as herbal remedy for +400 years in Korea
All three herbs are registered in Korea Food Standard Codex as main food material
Cynanchum wilfordii and Phlomis umbrosa are reported to be liver protective herbs by WHO

40. EnBio Estrogen Receptor / Coactivator, Ligand Assay System
Safety of EstroG-100 (2)
MCF-7 proliferation inhibition Inhibitory effect of proliferation of human breast cancer cell line (MCF-7)
Estrogen receptor binding affinity test
No binding affinity to both ERα & ERβ in estrogen receptor binding affinity study
EnBio Estrogen Receptor / Coactivator, Ligand Assay System

41. Safety of EstroG-100 (3) Toxicology Single oral toxicity study
No specific toxic symptoms in relation to test substance were observed
Minimal lethal dose (MLD) > 4,000 mg/kg (HED = 648.6mg/kg)
Thirteen-week repeated (91 day) oral dose toxicity study of in Sprague-Dawley rats
No observed adverse effect level (NOAEL):
upward 1,000 mg/kg in the male and female group
Genetic Toxicity Study – proven non-toxicity
Ames (Bacterial Reverse Mutation), Micronucleus, Chromosome Aberration

42. Mechanism of Action (1) EstroG-100:
There are 4 different traditional methods of screening candidate plants for estrogenecity.
E-screen assay to see non-reproductive tract target tissue response for a certain plant extract to induce alkaline phosphotase or ALP √ confirmed
Reproductive tract response for a certain plant extract to change uterus weight of ovariectomized rats (now, just for safety) √ confirmed
Receptor binding affinity test (now, just for safety) √ confirmed
Gene reporter vector assay (now, just for safety)
EstroG-100:
In a non-reproductive tract target tissue response for e-screen assay, all of the 3 constituent herbal extracts of EstroG-100 found to promote estrogen-specific ALP activity to show estrogenic action while EstroG-100 promoted more than any of the individual herbal extract (Lee et al. Anti-menopausal effect of the newly-developed phytoestrogen, FGF271 (=EstroG-100), in vitro and in vivo. Lab. Anim. Res. 24(2): (2008).) In the earlier study that has not been published, the 3 constituent herbal extracts of EstroG-100 were selected out of 71 different herbal extracts by this e-screen assay.

43. Mechanism of Action (2)
Even though the exact mechanism has not been clarified, the following available evidences suggest that some phytochemicals in EstroG-100 act as estrogen agonists and/or antagonists without influencing the levels of estradiol (E2) and follicle stimulating hormone or FSH:
In two researches for the reproductive tract target tissue response, EstroG-100 did not increase the uterus weight of ovariectomized rats while it increased femoral bone mineral density. (Kim et al. Korean J. Food Sci. Technol., 2008 and Lee et al. Lab. Anim. Res. 2008)
EstroG-100 did not show any affinity to both estrogen receptor alpha and beta in the receptor binding affinity test reported by Chungbuk National Univ. of South Korea
Each herbal extract of EstroG-100 showed inhibitory effect of the proliferation of human breast cancer (MCF-7) cells
In three randomized double-blind placebo controlled clinical study, EstroG-100 improved menopausal symptoms without any serious side effects with no increase of body weight and BMI and without influencing level of E2 and FSH (Lee et al. Evaluation of effectiveness and safety of natural plants extract (Estromon(=EstroG200)) on perimenopausal women for 1 year. J of Korean Society of Menopause. 11(1): (2005)
In other clinical study performed in U.S. that was finished on Feb. 2010, EstroG-100 significantly improved menopausal symptoms of non-Asian American women without any side effect (Chang et al. The Effect of Herbal Extract (EstroG-100®) on Pre-, Peri-, and Post-Menopausal Women: A Randomized Double-Blind Placebo-Controlled Study. Phytother. Res. 26: (2012)).

44. EstroG-100 D. Approvals & Licenses

45. Approvals & Licenses (NDI)
NDI Notification Accepted by US FDA (2010)
EstroG-100 is listed as New Dietary Ingredient
※ The Federal Food, Drug, and Cosmetic Act (the act) requires that manufacturers and distributors who wish to market dietary supplements that contain “new dietary ingredients” which has not been distributed in USA market before 1994, notify the Food and Drug Administration about these ingredients. Generally, the notification must include information that is the basis on which manufacturers/ distributors have concluded that a dietary supplement containing a new dietary ingredient will reasonably be expected to be safe under the conditions of use recommended or suggested in the labeling. The NDI notification process is complex. NDI notifications are most often rejected due to insufficient evidence for safety, the absence of required elements, as well as lack of knowledge and experience for such notifications.

46. Approvals & Licenses (NPN)
NHPD Product License, Health Canada (2011)
According to Health Claim, 10 Symptoms Improved!
Approved Claims with No Side Effects
According to Health Claim, 10 Symptoms Improved!
Date of License: July 5, 2011 Natural Product Number(NPN): Helps to relieve the symptoms associated with menopause such as hot flashes, night sweats, paresthesia(numbness on hands/foot), insomnia, nervousness, melancholia(depression), vertigo(dizziness) , fatigue, rheumatic pain and vaginal dryness.
Risk Information:
None.

47. Approvals & Licenses (HFFI)
Health Functional Food Ingredient (HFFI) Approval by MFDS (Korea FDA) (2010)
Approval No: Claim: Help with climacteric women’s health EstroG-100 is the first approved ingredient in Korea as Health Functional Food Ingredient by KFDA for alleviating menopausal symptoms such as hot flashes, night sweats, paresthesia(numbness on hand/foot), insomnia, nervousness, melancholia(depression), vertigo(dizziness), fatigue, rheumatic pain and vaginal dryness and formication

48. EU Approval Status N O W
Received Positive Assessment by Irish Authority ~
EU Member States reviewed the Irish Authority’s opinion
Final comments submitted to EU Member States for assessment on novel food approval for EstroG-100
Expecting to obtain Novel Food Approval

49. China Approval Status N O W Initiated branch establishment 2013.09
Established branch in China
Partner with Registration Agency
Delivered Samples for Examination
Applied for trademark for EstroG
Requested to examine product to authorized health food inspection institution
Technical Review by CFDA ~ ~
Administrative Review by CFDA
Decision Delivery by Administrative Service Center
~2016 N O W

50. Estrog-100 e. Products & Partners

51. Major Products & Partners
Supplying Ingredients for Global Clients in S. Korea, U.S., Canada, Singapore, Malaysia, Thailand
Major Products
Major Partners (Domestic)
EstroG Finished Goods
EstroG ODM
BAEKSUO GOONG
(GS Home Shopping, Home & Shopping,,, Hyundai Home Shopping)
BAEKSUO QUEEN
(Lotte & CJ Home Shopping)
Donga BAEKSUO
(Donga Pharm)
EstroG Ingredients
Major Partners (Overseas)
NU SKIN
(ESTERA Ⅱ)
HERBALIFE (Healthy Woman EstroG)
KGC
(Hwaaelak Queen)
Walgreens
(Menopause Relief)
CVS
(Menopause Relief)
DR’S BEST
(Best EstroG-100)
NOWFOODS
(Herbal Pause)

52. Products (US) Multi Symptom Menopause Relief (Walgreens)
8 Symptom Advanced
(CVS Pharmacy)
Herbal Pause
(NOW Foods)
Best EstroG-100
(Doctor's Best)
Advanced Natural Sex
for Women 50+
(Life Extension)
Ultra EstroG-100
(Swanson)
Profemin
(TheraBotanics LLC)
Intimate Comfort
(Healthy Directions )
Zestrogen
(Purity Products)
Advanced 8-Symptom Menopause Relief
(Meijer)
Venus and Mars
(Dr. John Gray, Inc.)
EstroPrime Plus
(Allergy Research Group)
Flashes No More
(Nutricology)
n-fuzed Estro-Fem
(Harmonic Innerprizes Inc)
HerbaEst Balance
(New Spirit Naturals)

53. Estrog-100 F. In-house Manufacturing Facility

54. In-house Manufacturing Facility
Securing supply of raw ingredients for GMP level manufacturing through contract farming
Contract Farming for EstroG Raw Material
Completed Construction of GMP Facility (September 2014)
Expected effect from in-house production
Strict control over quality
Profit increase by reducing production cost
Secure sustainable supply of ingredient through increase in Capacity
Stable supply of ingredients through contract farming
Capacity
Secure raw material supply through contract farming
(Ton)
300
300
Easy to grow & harvested annually in autumn.
In-house
CAPA
Total
High resistance to decay
160
120
In-house low temperature warehouse to ensure the best quality of raw materials
* In-house Production Capa of 10 ton/month

55. Estrog-100 G. MEDIA Coverage

56. Media Coverage (1)
EstroG-100® was mentioned on national Canada TV show, Steven and Chris on January 22nd, 2015.

57. Media Coverage (2)
SBS Special : Rediscovery of Korean Herb (Mar. 3rd , 2013)
The most popular privately owned TV channel, SBS Special Documentary featured EstroG-100 for 1 hour: its history, science & technology, testimonials from MDs and end users, and other distinctive aspects.
“Traditional Korean herb extracts pulling
Global attention and being exported to the
World.
KBS Science Café – Science of Hormone (April 9th, 2012)
The largest and state-run Korea Broadcasting System or KBS reported on hormone in their program called Science Café. It dealt the science of hormone and introduced EstroG-100 as a safe new product for menopause.

58. TV Commercial featuring on TV Commercial featuring on
Media Coverage (3)
TV Commercials & Others
TV Commercial featuring on
KBS and MBC
SBS News Health Report(July, 2012)
TV Commercial featuring on
KBS and MBC
MBC Power Magazine(Oct., 2012)

59. Press Coverage (1) Life Extension Magazine, May 2012
“EstroG-100™, this multi-compound extract supports balanced estrogenic activity, which in turn inhibits the many symptoms of menopause including female sexual dysfunction”

60. Press Coverage (2)
세계 각국
우량 협력업체

61. Home Shopping & Infomercial
Launched through 5 Major Home Shopping Channels in Korea
Launched through infomercial in US in June 2014

62. Estrog-100 H. Awards

63. Awards (1) 2014 Bronze Tower Industrial Order (Presidential Award),
Korea Creative Economy Expo
Awarded Presidential Bronze Tower Industrial Order Service Merit, in recognition of contribution to the development of industry and the national economy.

64. Awards (2)
Best Botanical Award at Natural Products Expo West in US (2014)

65. Awards (3) Korea’s Top 10 Most Innovative Technologies (2013)
Korean World-class Product Award (2011)
EstroG-100 was awarded for “Korea’s top 10 innovative technologies” in This award is given only for the product that is the most promising and potential of the year in all industry.
World-class Product Award is honorable recognition given to top-tier Korean companies including Samsung, Hyundai, and LG.
For ‘EstroG-100’ by Ministry of Trade, Industry and Energy
For ‘EstroG-100’ by Ministry of Knowledge & Economy

66. Awards (4) Presidential Citation (2011)
In recognition of the company’s integrated contribution to the growth of the industry through edge-state technology development in agro-fishery food sector.

67. Awards (5) IR52 Chang Young-Sil Award(2009)
This Award is normally and in most cases for conglomerates such as Samsung, Hyundai, LG, and for the suppliers for the big companies from Ministry of Education, Science and Technology (2009).

68. Korea Health Industry Award by KFDA 2009 Health Technology Award 2008
Awards (6)
Korea Health Industry Award by KFDA 2009
Health Technology Award 2008

69. Awards (7) Product Merit Award-NBJ (2006)
Awarded to the Promising Brand-new Functional Food of the Year

70. Awards (8)
Gold Medal Prize in the Exhibition of Inventions of Geneva (2008)
The International Exhibition of Inventions of Geneva is one of the three largest invention expo in the world.

71. Estrog-100 I. Miscellaneous

72. Product type-Examples (1)
Baeksuo Gung
Baeksuo Secret
Outer Packing
1 paper box
Inner
4 inner boxes
2 inner bottles
Contents
6 soft gels/Blister
5PTPs/inner box
Total 500mg x 120 capsules
(1 month)
56 tablets/bottle
Total 500mg x 112 tablets
(2 months)
Dosage
4 capsules per day
2 tablets per day
Formulation Types
Soft gels
Coated tablet
MOQ

73. Product type-Examples (2)
8 Symptom Advanced Menopause Relief (CVS)
Multi Symptom Menopause Relief (Walgreens)
Hwang Hoo Baeksuo
Outer Packing
1 paper box
Inner -
2 inner boxes
Contents
20 capsules/box
Total 514mg x 28 capsules
(1 month)
30 spout pack bags/inner box
Total 80g x 60 packs
Dosage
1 capsule per day
2 packs per day
Formulation Types
Hard capsule
Beverage
MOQ

74. Product type-Examples (3)
Baeksuo Hyoso
Baeksuo Queen
Outer Packing
1 paper box
Inner
2 paper boxes
Contents
30 packs/box
Total 3g x 60packs
(1 month)
14 packs/box
Total 22g x 28packs
Dosage
2 packs per day
1 pack per day
Formulation Types
Sachet powder
Jelly type
MOQ

75. Product type-Examples (4)
EstroG-100
Outer Packing
1 bottle
Inner -
Contents
615mg x 60 capsules
(1 month)
700mg x 60 tablets
Dosage
2 capsules per day
2 tablets per day
Formulation Types
Hard capsule
Tablet
MOQ

76. www.naturalendo.com Naturalendo Tech Co., Ltd.
3rd Floor, Bldg A. C’s Tower, 58, 255 St., Pankyo-ro
Bundang-gu, Seongnam-shi, Gyeonggi-do, Korea